Company intelligence / Profile preview

Calibrant Biosystems

Gaithersburg, Maryland, USA

Ownership: Private
Development stage: Other

Overview

Calibrant Biosystems was a biotechnology company specializing in high-throughput proteomics and biomarker discovery. The company developed the Gemini™ platform, a proprietary technology designed for the discovery of protein-based biomarkers and the mapping of protein-protein interactions. Its services and technology were primarily used to support drug discovery and development by identifying therapeutic targets and diagnostic markers. In 2011, the company was acquired by KBI Biopharma to integrate its advanced analytical and proteomic capabilities into KBI's biopharmaceutical development services.

Therapeutic areas: OncologyImmunology
Modalities: Protein
Industry: Drug Discovery Services

Beyond the preview

Go deeper on Calibrant Biosystems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calibrant Biosystems.

Explore the full profile